(Total Views: 577)
Posted On: 02/14/2022 12:59:46 PM
Post# of 154850
It is complicated:
Not to complicated. On the whole CCL5 has more negatives than positives when it comes to cancer. But you still want migration of the tumor killing cells to the cancer site. Using a CCL5 inhibitor would not be preferable because it might hamper migration. Using CCR5 blockade would highly limit the activation of CCL5 while allowing a lesser activation through the CCR1 and CCR3 receptors. Which would still allow migration while not ramping up an overactive CCL5 that can be devastating in cancer.
Quote:
CCL5 is responsible for the infiltration of a tumor by NK cells [48,49,52,53], conventional type 1 dendritic cells [54], T helper cell type 1 (Th1) [28], and type 1 cytotoxic cells (Tc1) [22]. For this reason, some postulate that cancer therapies should combine immunotherapy with increasing the expression of CCL5 in the tumor to enhance the infiltration of the tumor by various immune cells [30,49,50].
Not to complicated. On the whole CCL5 has more negatives than positives when it comes to cancer. But you still want migration of the tumor killing cells to the cancer site. Using a CCL5 inhibitor would not be preferable because it might hamper migration. Using CCR5 blockade would highly limit the activation of CCL5 while allowing a lesser activation through the CCR1 and CCR3 receptors. Which would still allow migration while not ramping up an overactive CCL5 that can be devastating in cancer.
(6)
(0)
